Jounce Therapeutics is a clinical-stage immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in several solid tumors; Pimivalimab, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and GS-1811, a monoclonal antibody that depletes T regulatory cells in the tumor microenvironment. We show 27 historical shares outstanding datapoints in our JNCE shares outstanding history coverage, used to compute JNCE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing JNCE market cap history over the course of time is important for investors
interested in comparing JNCE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of JNCE versus a peer is one thing; comparing
JNCE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like JNCE can fluctuate over the course of history.
With this page we aim to empower investors researching JNCE by allowing them to research the JNCE market cap history. |
Free JNCE Email Alerts:
Video: The Importance of Market Cap
